Treatment Histories for t-AML/t-MDS Patients
| Patient No. (UPN) . | Primary Tumor . | Primary Treatment* . | Status Before AML . | Latency Period to t-AML/ t-MDS* . | t-AML or t-MDS (date) . | Chromosome 21 Abnormality . |
|---|---|---|---|---|---|---|
| (A) Patients with balanced translocations of CBFA2 | ||||||
| 4. (2213) | Hodgkin’s Disease | 1980: RT only 1988, RL: MOPP × 6 mo, MOPP/ABVD × 3 mo 1990: Autologous BMT 1991, RL: RT/VP16 | CR, S/P autoBMT | 60 (60) mo | t-AML (1/93) | t(17;21) |
| 5. (2199) | Mantle Cell Lymphoma (BM+) | 1/91: COMLA-ABP (8 mo) Mitox/VP16 × 3 mo 6/94: Mitox/VP16 × 4 mo DHAP × 2 mo 12/94: HD-Cy autoBMT: Busulfan/Cy/Ara-C | CR, S/P autoBMT | 52 (52) mo | t-MDS (4/95) | t(15;21) |
| 6. (2161) | Hodgkin’s Disease (Stage 4B) | 9/86: MOPP × 9; RT to left spine 12/88: ABVD × 6 5/90: Cy + BCNU + Autologous PBSCT | Recurrent HD in BM 11/91 | 62 (36) mo | t-MDS (11/91) t-AML (12/91) | t(14;21) |
| 7. (70)† | Lung cancer undiff, extensive | CCNU, Vcr, Cy, VP16 × 18 mo | CR | 63 (63) mo | t-AML | t(1;21) |
| (B) Patients without balanced translocations of CBFA2‡ | ||||||
| 8. (2069) | Ovarian cancer | Surgery, Melphala × 1 year | CR | 33 mo | t-AML (10/83) | +der(21)t(15;21)(q21;q22) |
| 9. (2216) | Breast cancer 3/85 Graves disease 1980 | Lumpectomy, RT 131I | CR | 26 mo 7 yr | t-AML (6/87) | der(21)t(6;12;21;?)(21p13 → 21q11∷?∷21q11 → 21q22∷?12q21→ ?12q11∷6q14 → 6qter) |
| Patient No. (UPN) . | Primary Tumor . | Primary Treatment* . | Status Before AML . | Latency Period to t-AML/ t-MDS* . | t-AML or t-MDS (date) . | Chromosome 21 Abnormality . |
|---|---|---|---|---|---|---|
| (A) Patients with balanced translocations of CBFA2 | ||||||
| 4. (2213) | Hodgkin’s Disease | 1980: RT only 1988, RL: MOPP × 6 mo, MOPP/ABVD × 3 mo 1990: Autologous BMT 1991, RL: RT/VP16 | CR, S/P autoBMT | 60 (60) mo | t-AML (1/93) | t(17;21) |
| 5. (2199) | Mantle Cell Lymphoma (BM+) | 1/91: COMLA-ABP (8 mo) Mitox/VP16 × 3 mo 6/94: Mitox/VP16 × 4 mo DHAP × 2 mo 12/94: HD-Cy autoBMT: Busulfan/Cy/Ara-C | CR, S/P autoBMT | 52 (52) mo | t-MDS (4/95) | t(15;21) |
| 6. (2161) | Hodgkin’s Disease (Stage 4B) | 9/86: MOPP × 9; RT to left spine 12/88: ABVD × 6 5/90: Cy + BCNU + Autologous PBSCT | Recurrent HD in BM 11/91 | 62 (36) mo | t-MDS (11/91) t-AML (12/91) | t(14;21) |
| 7. (70)† | Lung cancer undiff, extensive | CCNU, Vcr, Cy, VP16 × 18 mo | CR | 63 (63) mo | t-AML | t(1;21) |
| (B) Patients without balanced translocations of CBFA2‡ | ||||||
| 8. (2069) | Ovarian cancer | Surgery, Melphala × 1 year | CR | 33 mo | t-AML (10/83) | +der(21)t(15;21)(q21;q22) |
| 9. (2216) | Breast cancer 3/85 Graves disease 1980 | Lumpectomy, RT 131I | CR | 26 mo 7 yr | t-AML (6/87) | der(21)t(6;12;21;?)(21p13 → 21q11∷?∷21q11 → 21q22∷?12q21→ ?12q11∷6q14 → 6qter) |
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; t, therapy-related; CR, complete response; RL, relapse; BMT, bone marrow transplant; PBSCT, peripheral blood stem cell transplant; RT, radiation therapy; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; Ara-C, cytarabine; BCNU, carmustine; CCNU, lomustine; COMLA-ABP, cytoxan, vincristine, MTX with leucovorin, Ara-C, adriamycin, bleomycin and prednisone; Cy, cyclophosphamide; DHAP, dexamethasone, high-dose Ara-C, cisplatin; Mitox, mitoxantrone; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; Mtx, methotrexate; Vcr, vincristine; VP16, etoposide; UPN, unique patient number.
Time from treatment with Topo II inhibitors is given in parentheses. Topo II inhibitors are indicated by boldface type.
Patient no. 70 in Pedersen-Bjergaard and Philip.12
Results of FISH analysis: patient no. 8: two normal chromosomes 21 were labeled in each cell examined; the +der(21) was not labeled by AML21 probes; however, FISH with a painting probe confirmed that the derivative gained was from chromosome 21. Patient no. 9: Only one normal chromosome 21 was labeled by AML21 probes; the der(21) was not labeled, indicating a loss of 21q22 sequences.